BrainsWay Ltd. Overview
Pro stress-test →BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology and has obtained three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy.
Strategic Profile
Pro stress-test →Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Israel Ministry of Defense's Rehabilitation Department has granted approval for the reimbursement of Deep TMS therapy for qualifying patients with post-traumatic stress disorder (PTSD) at Israeli public hospitals, expanding the company's addressable market and establishing strong domestic reimbursement pathways.
Competitive Landscape
Pro stress-test →MagVenture is one of BrainsWay's competitors in the transcranial magnetic stimulation market. BrainsWay differentiates through its H-coil technology enabling deeper brain penetration, exclusive NIH patent license, and unique portfolio of multiple FDA-cleared indications, positioning it as the market leader in the deep TMS segment.
Industry Context
BrainsWay Ltd. operates in Medical Devices - Neurostimulation/Psychiatry.
Key facts
Founded: 2003 · Headquarters: Jerusalem, Israel · Employees: 120 · Revenue: $46.1M · Market cap: $281M